$NVUS Key results to be released in June. Strong watch.

*******June is setting up to a very big month for NASDAQ:NVUS and some very profitable trades may on the offering,. Keep track of the notable dates listed below for results and presentations. Accumulation has already began in anticipation of positive news. **********

AVERAGE ANALYSTS PRICE TARGET $8.75
AVERAGE ANALYSTS RECOMMENDATION BUY

UPCOMING MARKET MOVING EVENTS
June 2019 – Results of OP0201 phase 1 study C-002
June 2019 – Poster presentation of OP0201 phase 1 study C-001 data at the 20th International Symposium on Recent Advances in Otitis Media (June 9-13, Los Angeles, CA)
1H 2020 – Results of OP0201 phase 2a study C-006

COMPANY PROFILE
Novus Therapeutics, Inc. is a pharmaceutical company. It focused on the acquisition, development and commercialization of ear, nose and throat products. The company's platform consists of OP-01 Foam Platform and OP-02 Surfactant Program. Novus Therapeutics, Inc., formerly known as Tokai Pharmaceuticals Inc